Overview

* Design Therapeutics ( DSGN ) Q2 net loss of $19.1 mln misses analyst expectations

* Favorable PK data for DT-216P2 in Friedreich Ataxia; U.S. trials on hold

Outlook

* Company plans to address FDA clinical hold with clinical data

Result Drivers

* FDA HOLD - U.S. trials for DT-216P2 are on hold due to FDA concerns about starting dose, with plans to address using clinical and nonclinical data

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Miss -$19.08 -$18.90

Income mln mln (3

Analysts

)

Q2 Basic -$0.34

EPS

Q2 $21.57

Operatin mln

g

Expenses

Q2 -$21.57

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Design Therapeutics Inc ( DSGN ) is $5.00, about 13% above its August 6 closing price of $4.35

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)